Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gan & Lee Pharmaceuticals

http://www.ganlee.com/en/

Latest From Gan & Lee Pharmaceuticals

China’s First Insulin Tender Hits Multinationals Hard

An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.

China Pricing Strategies

China Offers Level Field In Trade Pact Bid But Multiple Pharma Barriers Remain

China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.

China Generic Drugs

Sandoz Partner Gan & Lee Wraps Phase III Insulin Glargine Trial

Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).

Biosimilars Clinical Trials

China Rings In New Year With Major Deals, Record IPOs And Trends To Watch

From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.

China Commercial
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Gan & Lee Pharmaceuticals Shandong Co., Ltd
    • Gangan Medical Technology Jiangsu Co., Ltd.
UsernamePublicRestriction

Register